We believe that the genomic region hosting this pseudoexon should be included in the molecular screening of LGMDR4 patients, especially those presenting a single SGCB pathogenic variant with moderate or severe sarcoglycans deficiency in muscle. This evidence concerns the gene SGCB and hyperinsulinemic hypoglycemia, familial, 4.